“Medannex is a fantastic example of an ambitious Scottish company that’s developing innovative new treatments for patients globally.”

Jim Watson, Director of
Innovation & Enterprise
Services at Scottish Enterprise

Medannex Ltd is a privately-owned biopharmaceutical
company based in Edinburgh, Scotland.

Founded by serial life sciences entrepreneur Professor Chris Wood (winner of the ‘Lifetime Achievement Award’ at Scotland’s Life Sciences Annual Awards 2021), Medannex is developing novel treatments to improve the lives of people impacted by cancers and autoimmune diseases.

MDX-124 is the only therapeutic to target annexin-A1, a protein that plays a key role in the development of cancer, autoimmunity and other diseases.

Medannex has established research collaborations with oncology and autoimmunity experts at leading institutions including:

– University of Oxford
– University of Glasgow
– Mayo Clinic, Arizona
– University of Edinburgh
– University of Liverpool
– University College London
– ARU, Cambridge
– Brighton & Sussex Medical School
– The Beatson West of Scotland Cancer Centre
– The Christie, Manchester

 

Collaborations & Affiliations

Medannex is proud to collaborate with leading academic researchers, play an active role within several industry associations and provide extensive skills development opportunities.